Randomised open-label trial of insulin lispro protamin suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients

被引：0
|
作者：
Giugliano, D.
Cleall, S.
Pontiroli, A. E.
Koivisto, V.
机构：
来源：
DIABETOLOGIA | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1037
引用
收藏
页码：S421 / S422
页数：2
相关论文
共 50 条
  • [41] Comparison of Insulin Glargine vs. NPH Insulin in Basal-Bolus Therapies in T2DM Patients and CKD: Preliminary Results of a Prospective, Randomized, Open-Label Trial
    Rocha Betonico, Carolina Castro
    De Oliveira Titan, Silvia Maria
    Correa-Giannella, Maria Lucia
    Nery, Marcia
    Queiroz, Marcia Silva
    DIABETES, 2016, 65 : A144 - A145
  • [42] Efficacy and safety of insulin glulisine and insulin lispro combined with insulin glargine in patients with Type 1 diabetes
    Prager, R
    Dreyer, M
    Robinson, A
    Busch, K
    Penfornis, A
    Souhami, E
    DIABETOLOGIA, 2004, 47 : A301 - A301
  • [43] Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
    Yoon, Kun-Ho
    Hardy, Elise
    Han, Jenny
    DIABETES & METABOLISM JOURNAL, 2017, 41 (01) : 69 - 74
  • [44] Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial
    Zinman, Bernard
    Fulcher, Greg
    Rao, Paturi V.
    Thomas, Nihal
    Endahl, Lars A.
    Johansen, Thue
    Lindh, Rebecka
    Lewin, Andrew
    Rosenstock, Julio
    Pinget, Michel
    Mathieu, Chantal
    LANCET, 2011, 377 (9769): : 924 - 931
  • [45] Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
    Blonde, Lawrence
    Jendle, Johan
    Gross, Jorge
    Woo, Vincent
    Jiang, Honghua
    Fahrbach, Jessie L.
    Milicevic, Zvonko
    LANCET, 2015, 385 (9982): : 2057 - 2066
  • [46] A comparison of prandial premixed (ILPS/lispro) vs basal bolus (glargine/lispro) insulin therapy in obese patients with type 2 diabetes (T2D)
    Ahmann, Andrew
    Jiang, Honghua
    Martin, Sherry A.
    DIABETES, 2008, 57 : A564 - A564
  • [47] Hypoglycemia rates with titration of prandial premixed (ILPS/lispro) or basal bolus (glargine/lispro) insulin therapy in patients with type 2 diabetes (T2D)
    Ahmann, Andrew
    Jiang, Honghua
    Martin, Sherry A.
    DIABETES, 2008, 57 : A146 - A146
  • [48] Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes
    Giugliano, Dario
    Esposito, Katherine
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2012, 3 (03) : 99 - 106
  • [49] A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1
    Garg, S.
    Dreyer, M.
    Jinnouchi, H.
    Mou, J.
    Qu, Y.
    Hartman, M. L.
    Rosilio, M.
    Jacober, S. J.
    Bastyr, E. J., III
    DIABETES OBESITY & METABOLISM, 2016, 18 : 25 - 33
  • [50] Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
    Russell-Jones, David
    Babazono, Tetsuya
    Cailleteau, Roman
    Engberg, Susanne
    Irace, Concetta
    Kjaersgaard, Maiken Ina Siegismund
    Mathieu, Chantal
    Rosenstock, Julio
    Woo, Vincent
    Klonoff, David C.
    LANCET, 2023, 402 (10413): : 1636 - 1647
12345